Distribution of HK2 Positive Tumors in Groups Defined by Clinicopathological Variables.

<p>Distribution of HK2 Positive Tumors in Groups Defined by Clinicopathological Variables.</p

Summary of SEER Reported Characteristics for 169 patients with HCC.

<p>Summary of SEER Reported Characteristics for 169 patients with HCC.</p

Photomicrographs of HCC tissue specimens stained using anti-CKA antibody.

<p>Images magnified at 200×. A) Normal liver tissue demonstrates an absence of immunohistochemical staining. B) Corresponding HCC tumor specimen from the same patient demonstrates mild cytoplasmic staining of moderately-differentiated tumor cells. C) Moderately-differentiated HCC nested within an area of fibrosis. The tumor cells demonstrate moderate cytoplasmic and nuclear staining.</p

Patterns of overall survival (OS) based on tumor immunohistochemical expression of CKA and HK2.

<p>Solid lines represent immunohistochemistry-positive cases while dotted lines represent immunohistochemistry-negative cases. A) OS was significantly worse for patients with CKA-positive tumors relative to patients with CKA-negative tumors (Log-Rank test p = 0.03). B) OS was also significantly worse for patients with HK2-positive tumors relative to patients with HK2-negative tumors (Log-Rank test p = 0.003). C) Among stage I and II HCC patients, OS was significantly worse for patients with CKA-positive tumors relative to patients with CKA-negative tumors (Log-rank p = 0.03). D) Among stage I and II HCC patients, OS was also significantly worse for patients with HK2-positive tumors relative to patients with HK2-negative tumors (Log-rank p = 0.02). E) Among patients with HK2-negative tumors, OS did not differ significantly on the basis of CKA expression (Log-Rank test p = 0.53). F) Among patients with HK2-positive tumors, OS was significantly worse in patients whose tumors were also CKA-positive (Log-Rank test p = 0.04). G) Among patients with CKA-negative tumors, OS did not differ significantly on the basis of HK2 expression (Log-Rank test p = 0.35). H) Among patients with CKA-positive tumors, OS was significantly worse in patients whose tumors were also HK2-positive (Log-Rank test p = 0.01).</p

Expression of BRCA1-IRIS in breast tumor samples.

<p>(A) DAPI stained HME cells transfected with Myc-tagged BRCA1-IRIS cDNA. Same cell stained with anti-Myc (red, B), anti-BRCA1-IRIS (green, C). (D) Merge of B and C. (E) Expression of BRCA1-IRIS in HME or BRCA1-IRIS overexpressing cells (IRIS) following transfection of luciferase or BRCA1-IRIS siRNA. (F and G) are low and high magnification images of invasive breast cancer section stained with pre-absorbed anti-BRCA1-IRIS antibody. Expression of BRCA1-IRIS in paraffin embedded normal mammary epithelial tissue (H and I), DCIS (J and K) or invasive breast cancer tissues (L and M). H, J and L are low magnification images, whereas I, K and M are high magnification images. Note the BRCA1-IRIS-psoitive (solid arrow) and -negative (dashed arrow) cells in K. Also note that while all sections are counter stained with hematoxylin, for technical reasons, the staining was done for shorter time in J, K, L and M compared to F, G, H and I. (N) Expression of 18S and BRCA1-IRIS mRNA (in duplicates) in 5 normal (N) and 19 breast tumors (T). Bars are, 400 µm in H, J, 200 µm in F, K and L, 100 µm in I and M and 50 µm in G.</p

Relationships between BRCA1-IRIS level and marker expression and tumor characteristics in Her2⁺ and TN/BL breast cancer tumor samples.

a<p>Spearman rank coefficient test correlation (r),</p>b<p>Spearman rank coefficient test <i>p</i>-value,</p>c<p>To compare multiple groups with one control group, analysis of variance (ANOVA) was used.</p><p><i>p</i>-values (two-sided) <0.05 were considered statistically significant.</p

Correlations between BRCA1-IRIS expression and AKT1, AKT2, p-AKT and survivin in breast tumor samples.

<p>Nonparametric <i>Spearman rank correlation test</i> comparing BRCA-IRIS and AKT1, AKT2, p-AKT, and survivin on 326 breast tumors TMAs. The staining for each marker was scored as described in the text and the results were blotted. Insets show Spearman correlation coefficient (r) and <i>p</i>-value for each correlation.</p

Immunohistochemical and pathologic characteristics significantly different in LT/Ras^V12<i>vs.</i> LT/IRIS subcutaneous tumors.

<p>Immunohistochemical and pathologic characteristics significantly different in LT/Ras^V12<i>vs.</i> LT/IRIS subcutaneous tumors.</p

Expression of BRCA1-IRIS, AKT1, AKT2, p-AKT, survivin and BRCA/p220 in breast tumors.

<p>Representative sections of TN/BL breast tumor tissues showing low (A, B, C, G, H, and I) and high (D, E, F, J, K, and L) magnification images of sections stained for BRCA1-IRIS (A and D), AKT1 (B and E), AKT2 (C and F), p-AKT (D and J), survivin (H and K), and BRCA1/p220 (I and L). Bars are 400 µm in A–D and 200 µm in E–H.</p

The association between BRCA1-IRIS overexpression and overexpression/activation of AKT and survivin in breast tumors.

<p>a is Fisher's exact <i>p</i>-value.</p